deCODE genetics Announces Third Quarter 2007 Financi... (e have recently completed two studiescon...)

deCODE genetics Announces Third Quarter 2007 Financial Results

Date:11/5/2007

e have recently completed two studies confirming the lack of undesirable drug-drug interactions, as well as a pharmacology study of its effects in the presence and absence of aspirin. The results of that study provide further evidence that DG041 inhibits platelet activation and aggregation through a crucial pathway that is not targeted by existing medications. In order to manage risk and expand our therapeutic pipeline, we are actively investigating partnership opportunities for these and earlier stage programs. Our financial results this year demonstrate our ability to create valuable assets through product development while leveraging our capabilities to generate near-term revenue streams," Dr. Stefansson concluded.

Recent highlights include:

Product Development

-- Heart attack. In its drug development program targeting the leukotriene

pathway for the prevention of heart attack, deCODE last month began

enrolling patients for its Phase IIa clinical trial for DG051, the

company's leukotriene A4 hydrolase inhibitor. In Phase I studies

completed earlier this year, DG051 significantly reduced the production

of leukotriene B4 (LTB4) in a dose dependent manner. LTB4 is a pro-

inflammatory molecule that deCODE's gene discovery and functional

biology work identified as a key factor in modulating risk of heart

attack. The Phase I studies showed DG051 to be safe and well-tolerated

at all dose levels tested, with a favourable pharmacokinetic profile.

DG051 was also recently evaluated in a 28-day Phase I study that

further demonstrated that the drug can deliver significant, sustained

reductions in LTB4 levels with once-daily dosing. The Phase IIa is a

randomized, double-blind, placebo-controlled trial that will examine

the impact of DG051 on the production of LTB4 as well as the compound's

pharmacokinetic and safety and tole
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
2. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
3. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
4. Response Genetics Reports Second Quarter 2007 Financial Results
5. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
8. Interleukin Genetics Announces Management and Board Appointments
9. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
10. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
11. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products

Post Your Comments:

deCODE genetics Announces Third Quarter 2007 Financi...(e have recently completed two studiescon...)